Completed PHASE2 INTERVENTIONAL 2-arm NCT01243086

OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab (STAR)

Sponsor: Hamilton Health Sciences Corporation

Updated 7 times since 2017 Last updated: Apr 5, 2018 Started: Mar 31, 2011 Primary completion: May 31, 2015 Completion: May 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Wet Macular Degeneration and is currently completed. Hamilton Health Sciences Corporation leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
May 2018 — Jun 2018 [monthly]

Completed PHASE2

Status: Unknown Status → Completed

▶ Show 2 earlier versions

May 2017 — May 2018 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2017 — May 2017 [monthly]

Recruiting PHASE2

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hamilton Health Sciences Corporation
McMaster University
St. Joseph's Healthcare Hamilton

Data source: McMaster University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hamilton, Canada